Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (687) 687
science & technology (579) 579
life sciences & biomedicine (553) 553
female (405) 405
male (377) 377
aminopyridines - adverse effects (354) 354
aminopyridines - therapeutic use (350) 350
middle aged (263) 263
adult (244) 244
aminopyridines - pharmacology (240) 240
aminopyridines - administration & dosage (239) 239
animals (222) 222
aged (190) 190
pharmacology & pharmacy (179) 179
benzamides - therapeutic use (135) 135
biological and medical sciences (129) 129
medical sciences (128) 128
treatment outcome (121) 121
pulmonary disease, chronic obstructive - drug therapy (118) 118
oncology (116) 116
cyclopropanes - therapeutic use (113) 113
roflumilast (112) 112
aminopyridines - pharmacokinetics (108) 108
benzamides - adverse effects (108) 108
respiratory system (105) 105
abridged index medicus (102) 102
double-blind method (96) 96
cyclopropanes - adverse effects (94) 94
mice (90) 90
benzamides - pharmacology (87) 87
dose-response relationship, drug (87) 87
drug therapy (86) 86
pharmacology. drug treatments (82) 82
research (80) 80
administration, oral (79) 79
care and treatment (79) 79
cyclopropanes - pharmacology (75) 75
general & internal medicine (74) 74
benzamides - administration & dosage (72) 72
phosphodiesterase 4 inhibitors - therapeutic use (71) 71
breast neoplasms - drug therapy (68) 68
aminopyridines (66) 66
chronic obstructive pulmonary disease (65) 65
adolescent (64) 64
young adult (64) 64
analysis (63) 63
cyclopropanes - administration & dosage (63) 63
dosage and administration (63) 63
patients (63) 63
breast cancer (62) 62
clinical trials (59) 59
mutation (59) 59
phosphodiesterase 4 inhibitors - adverse effects (58) 58
rats (57) 57
amrinone (56) 56
disease models, animal (55) 55
medicine & public health (55) 55
drug therapy, combination (54) 54
clinical trials as topic (53) 53
medicine, general & internal (51) 51
neurosciences & neurology (51) 51
breast neoplasms - pathology (48) 48
heart failure - drug therapy (48) 48
tumors (48) 48
drug interactions (47) 47
aged, 80 and over (46) 46
analgesics - adverse effects (46) 46
cyclin-dependent kinase 4 - antagonists & inhibitors (46) 46
phosphodiesterase 4 inhibitors - pharmacology (46) 46
benzamides - pharmacokinetics (45) 45
cancer (45) 45
time factors (45) 45
lung diseases, obstructive (44) 44
phosphodiesterase inhibitors - therapeutic use (44) 44
cyclin-dependent kinase 6 - antagonists & inhibitors (43) 43
pharmacokinetics (43) 43
kinases (42) 42
pulmonary disease, chronic obstructive - physiopathology (42) 42
cystic fibrosis - drug therapy (41) 41
disease progression (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
cystic fibrosis (40) 40
pharmacology (40) 40
cyclopropanes - pharmacokinetics (39) 39
neurosciences (38) 38
studies (38) 38
antineoplastic agents - adverse effects (37) 37
bronchodilator agents - therapeutic use (37) 37
internal medicine (37) 37
pharmacology/toxicology (37) 37
phosphodiesterase 4 inhibitors - administration & dosage (37) 37
cystic fibrosis transmembrane conductance regulator - genetics (36) 36
proteins (36) 36
cardiotonic agents - therapeutic use (35) 35
phosphodiesterase 4 inhibitors (35) 35
pulmonary/respiratory (35) 35
quinolones - therapeutic use (35) 35
4-aminopyridine (34) 34
asthma (34) 34
copd (34) 34
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (786) 786
German (29) 29
Spanish (5) 5
French (4) 4
Japanese (4) 4
Russian (2) 2
Italian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
by Chong, Jimmy and Leung, Bonnie and Poole, Phillippa and Poole, Phillippa
Cochrane library, ISSN 1469-493X, 09/2017, Volume 2017, Issue 9, pp. CD002309 - CD002309
Aminopyridines | Lungs & airways | Administration, Oral | Pulmonary Disease, Chronic Obstructive | Cyclopropanes | Disease Progression | Randomized Controlled Trials as Topic | Forced Expiratory Volume | Chronic obstructive pulmonary disease (stable) | Phosphodiesterase 4 Inhibitors | Quality of Life | Nitriles | Chronic obstructive pulmonary disease, stable ‐ pharmacotherapy | Cyclohexanecarboxylic Acids | Benzamides | Medicine General & Introductory Medical Sciences | Phosphodiesterases | Other medications | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Aminopyridines - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Cyclohexanecarboxylic Acids - adverse effects | Aminopyridines - adverse effects | Cyclohexanecarboxylic Acids - administration & dosage | Cyclopropanes - adverse effects | Nitriles - administration & dosage | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Nitriles - adverse effects | Benzamides - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
by Martinez, Fernando J, Prof and Calverley, Peter M A, Prof and Goehring, Udo-Michael, MD and Brose, Manja, MSc and Fabbri, Leonardo M, Prof and Rabe, Klaus F, Prof
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9971, pp. 857 - 866
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Bronchodilator Agents - therapeutic use | Glucocorticoids - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Cyclopropanes - adverse effects | Cyclopropanes - therapeutic use | Vital Capacity - drug effects | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Phosphodiesterase 4 Inhibitors - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Drug Therapy, Combination | Benzamides - adverse effects | Double-Blind Method | Phosphodiesterase 4 Inhibitors - therapeutic use | Treatment Outcome | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Chronic diseases | Clinical trials | Care and treatment | Lung diseases, Obstructive | Corticosteroids | Chronic obstructive pulmonary disease | Inhibitor drugs | Drug therapy | Drug dosages | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
by Stein, Eytan M and DiNardo, Courtney D and Pollyea, Daniel A and Fathi, Amir T and Roboz, Gail J and Altman, Jessica K and Stone, Richard M and DeAngelo, Daniel J and Levine, Ross L and Flinn, Ian W and Kantarjian, Hagop M and Collins, Robert and Patel, Manish R and Frankel, Arthur E and Stein, Anthony and Sekeres, Mikkael A and Swords, Ronan T and Medeiros, Bruno C and Willekens, Christophe and Vyas, Paresh and Tosolini, Alessandra and Xu, Qiang and Knight, Robert D and Yen, Katharine E and Agresta, Sam and de Botton, Stephane and Tallman, Martin S
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 722 - 731
Life Sciences & Biomedicine | Hematology | Science & Technology | Triazines - therapeutic use | Humans | Middle Aged | Aminopyridines - pharmacokinetics | Aminopyridines - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - therapeutic use | Isocitrate Dehydrogenase - antagonists & inhibitors | Neoplasm Recurrence, Local - pathology | Young Adult | Aminopyridines - therapeutic use | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Bone Marrow - metabolism | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Antineoplastic Agents - pharmacokinetics | Bone Marrow - drug effects | Enzyme Inhibitors - adverse effects | Leukemia, Myeloid, Acute - pathology | Isocitrate Dehydrogenase - genetics | Enzyme Inhibitors - therapeutic use | Maximum Tolerated Dose | Bone Marrow - pathology | Neoplasm Recurrence, Local - genetics | Triazines - adverse effects | Aged | Mutation | Leukemia, Myeloid, Acute - genetics | Triazines - pharmacokinetics | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
by Loibl, Sibylle and de la Pena, Lorena and Nekljudova, Valentina and Zardavas, Dimitrios and Michiels, Stefan and Denkert, Carsten and Rezai, Mahdi and Bermejo, Begoña and Untch, Michael and Lee, Soo Chin and Turri, Sabine and Urban, Patrick and Kümmel, Sherko and Steger, Guenther and Gombos, Andrea and Lux, Michael and Piccart, Martine J and Von Minckwitz, Gunter and Baselga, José and Loi, Sherene
European journal of cancer (1990), ISSN 0959-8049, 11/2017, Volume 85, pp. 133 - 145
Buparlisib | Neoadjuvant | NeoPHOEBE | HER2 | Primary breast cancer | pCR | Life Sciences & Biomedicine | Oncology | Science & Technology | Class I Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Protein Kinase Inhibitors - adverse effects | Early Termination of Clinical Trials | Breast Neoplasms - enzymology | Time Factors | Biomarkers, Tumor - metabolism | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Chemical and Drug Induced Liver Injury - etiology | Morpholines - adverse effects | Aminopyridines - administration & dosage | Double-Blind Method | Europe | Morpholines - administration & dosage | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Lymphocytes, Tumor-Infiltrating - drug effects | Breast Neoplasms - drug therapy | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Breast Neoplasms - pathology | Neoadjuvant Therapy - adverse effects | Aged | Biomarkers, Tumor - genetics | Mutation | Australia | Antimitotic agents | Clinical trials | Product development | Breast cancer | Antineoplastic agents | Therapy | Toxicity | Liver | Taxane | Patients | ErbB-2 protein | Subgroups | 1-Phosphatidylinositol 3-kinase | Randomization | Epidermal growth factor | Inhibitors | Lymphocytes | Paclitaxel | Growth factors | Trastuzumab | Cancer | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma
by Bateman, Eric D., MD and Goehring, Udo-Michael, MD and Richard, Frank, MD and Watz, Henrik, MD
Journal of allergy and clinical immunology, ISSN 0091-6749, 2016, Volume 138, Issue 1, pp. 142 - 149.e8
Allergy and Immunology | phosphodiesterase 4 inhibitors | roflumilast | montelukast | Asthma | Allergy | Immunology | Life Sciences & Biomedicine | Science & Technology | Anti-Asthmatic Agents - adverse effects | Spirometry | Acetates - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Cyclopropanes - adverse effects | Quinolines - administration & dosage | Cyclopropanes - therapeutic use | Forced Expiratory Volume | Benzamides - administration & dosage | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Cyclopropanes - administration & dosage | Leukotriene Antagonists - administration & dosage | Aged, 80 and over | Female | Acetates - therapeutic use | Leukocyte Count | Drug Therapy, Combination | Benzamides - adverse effects | Leukotriene Antagonists - adverse effects | Leukotriene Antagonists - therapeutic use | Asthma - diagnosis | Severity of Illness Index | Aminopyridines - administration & dosage | Risk Factors | Treatment Outcome | Asthma - drug therapy | Disease Progression | Acetates - administration & dosage | Aged | Quinolines - therapeutic use | Anti-Asthmatic Agents - administration & dosage | Quinolines - adverse effects | Care and treatment | Research institutes | Analysis | Medical research | Medicine, Experimental | Respiratory agents | Roflumilast | Genotype & phenotype | Neutrophils | Chronic obstructive pulmonary disease | Infections | Bronchitis | Patients | Methods | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
by Bedard, Philippe L and Tabernero, Josep and Janku, Filip and A.wainberg, Zev and Paz-Ares, Luis and Vansteenkiste, Johan and Cutsem, Eric Van and Pérez-García, José and Stathis, Anastasios and Britten, Carolyn D and Le, Ngocdiep and Carter, Kirsten and Demanse, David and Csonka, Denes and Peters, Malte and Zubel, Angela and Nauwelaerts, Heidi and Sessa, Cristiana
Clinical cancer research, ISSN 1078-0432, 02/2015, Volume 21, Issue 4, pp. 730 - 738
Life Sciences & Biomedicine | Oncology | Science & Technology | Aminopyridines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Morpholines - administration & dosage | Pyrimidinones - adverse effects | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasms - mortality | Male | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Disease-Free Survival | Pyridones - administration & dosage | Maximum Tolerated Dose | Aged, 80 and over | Adult | Female | Aged | Pyrimidinones - administration & dosage | Morpholines - adverse effects | Pyridones - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial
by Ratjen, Felix, Prof and Hug, Christopher, MD and Marigowda, Gautham, MD and Tian, Simon, MD and Huang, Xiaohong, PhD and Stanojevic, Sanja, PhD and Milla, Carlos E, MD and Robinson, Paul D, MBChB and Waltz, David, MD and Davies, Jane C, Prof and VX14-809-109 investigator group and VX14-809-109 Investigator Grp
The lancet respiratory medicine, ISSN 2213-2600, 2017, Volume 5, Issue 7, pp. 557 - 567
Pulmonary/Respiratory | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Humans | Aminopyridines - adverse effects | Male | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Mucociliary Clearance - drug effects | Forced Expiratory Volume | Sweat - chemistry | Quinolones - adverse effects | Benzodioxoles - adverse effects | Female | Surveys and Questionnaires | Child | Aminopyridines - administration & dosage | Double-Blind Method | Lung - physiopathology | Quinolones - administration & dosage | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Lung - drug effects | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Dosage and administration | Drug therapy | Clinical trials | Care and treatment | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
by Wainwright, Claire E and Elborn, J. Stuart and Ramsey, Bonnie W and Marigowda, Gautham and Huang, Xiaohong and Cipolli, Marco and Colombo, Carla and Davies, Jane C and De Boeck, Kris and Flume, Patrick A and Konstan, Michael W and McColley, Susanna A and McCoy, Karen and McKone, Edward F and Munck, Anne and Ratjen, Felix and Rowe, Steven M and Waltz, David and Boyle, Michael P and TRAFFIC Study Grp and TRANSPORT Study Grp and TRANSPORT Study Group and TRAFFIC Study Group
The New England journal of medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 220 - 231
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Aminopyridines - adverse effects | Hospitalization - statistics & numerical data | Male | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Young Adult | Quinolones - adverse effects | Adult | Benzodioxoles - adverse effects | Female | Drug Therapy, Combination | Child | Aminopyridines - administration & dosage | Double-Blind Method | Homozygote | Quinolones - administration & dosage | Cystic Fibrosis - genetics | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Clinical trials | Cystic fibrosis | Care and treatment | Ivacaftor | Usage | Dosage and administration | Studies | Proteins | Intravenous administration | Antibiotics | Conductance | Drug therapy | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights